ReviewCell communication and signaling : CCS2026
CCL20-CCR6 axis in autoimmune disease and cancer progression: clinical and therapeutic implications.
Review in Cell communication and signaling : CCS, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
C-C motif chemokine ligand 20 (CCL20) is widely expressed in various human tissues and immune cells, playing a critical role in immune cell migration and inflammation. As the sole ligand of CCL20, C-C motif chemokine receptor 6 (CCR6) is a G protein-coupled receptor mainly expressed in immune cells and mediates chemotactic function of CCL20. The CCL20-CCR6 axis actively participates in immune homeostasis and activation. Dysregulation of CCL20-CCR6 axis is regarded as an imperative part of the pathogenic mechanism of autoimmune diseases and cancers, and a multitude of therapeutic strategies have been developed to target CCL20-CCR6 axis. In this review, we comprehensively summarized researches of CCL20-CCR6 axis and introduced the biology and functions of CCL20-CCR6 under normal conditions. We further discussed the pivotal pathogenic roles of CCL20-CCR6 axis in progression of autoimmune diseases as well as cancers from multiple directions. The article also explored recent advancements in the field of CCL20-CCR6 axis inhibition in autoimmune diseases and cancers, shedding light on its potential as a promising therapeutic target. A systematic understanding of CCL20-CCR6 axis in progression of autoimmune diseases and cancers is crucial for realizing the full potential of CCL20-CCR6 axis-based interventions, heralding the promise of improved outcomes for patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.